評估GLP-1類似物療法之反應的方法

Translated title of the contribution: METHOD FOR PREDICTING THE RESPONSE TO GLUCAGON-LIKE PEPTIDE-1 ANALOGUE THERAPY

Chia-Hung Lin (Inventor), Chi-Neu Tsai (Inventor)

Research output: Patent

Abstract

The present invention relates to methods that use novel biomarkers for predicting the response to glucagon-like peptide-1 (GLP-1) analogue therapy in a diabetic patient. The novel biomarkers of the invention show altered cytosine methylations state of certain CpG loci and the presence of a specific single nucleotide polymorphism (SNP) in diabetic patient less responsive to Glucagon-like peptide-1 (GLP-1) analogue to relative to diabetic subject responsive GLP-1 analogue.
Translated title of the contributionMETHOD FOR PREDICTING THE RESPONSE TO GLUCAGON-LIKE PEPTIDE-1 ANALOGUE THERAPY
Original languageChinese (Traditional)
IPCG01N 33/68(2006.01); G01N 33/74(2006.01)
StatePublished - 01 03 2022

Bibliographical note

公開公告號: 2.02208857E8
Announcement ID: 2.02208857E8

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-being

Fingerprint

Dive into the research topics of 'METHOD FOR PREDICTING THE RESPONSE TO GLUCAGON-LIKE PEPTIDE-1 ANALOGUE THERAPY'. Together they form a unique fingerprint.
View full fingerprint

Cite this